Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
Archives of Neurology
|
May 13, 2009
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study
Aaron Boster, Stephanie Hreha, Joseph R Berger, et al.
Scientific Reports
|
May 16, 2026
The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis
Delphine Van Laethem, Lars Costers, Augusto Miravalle, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 9, 2021
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Alasdair J Coles, Joanne L Jones, Patrick Vermersch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 2, 2019
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
Bart Van Wijmeersch, Barry A Singer, Aaron Boster, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
August 30, 2022
Toward Precision Phenotyping of Multiple Sclerosis
David Pitt, Chih Hung Lo, Susan A Gauthier, et al.
Frontiers in Neurology
|
April 11, 2019
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
Krista Barclay, Robert Carruthers, Anthony Traboulsee, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
Archives of Neurology
|
May 13, 2009
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study
Aaron Boster, Stephanie Hreha, Joseph R Berger, et al.
Scientific Reports
|
May 16, 2026
The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis
Delphine Van Laethem, Lars Costers, Augusto Miravalle, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 9, 2021
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Alasdair J Coles, Joanne L Jones, Patrick Vermersch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 2, 2019
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
Bart Van Wijmeersch, Barry A Singer, Aaron Boster, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
August 30, 2022
Toward Precision Phenotyping of Multiple Sclerosis
David Pitt, Chih Hung Lo, Susan A Gauthier, et al.
Frontiers in Neurology
|
April 11, 2019
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
Krista Barclay, Robert Carruthers, Anthony Traboulsee, et al.
Page
of 3